Objective: Myofascial trigger points (MTrPs) are focal disruptions in the skeletal muscle that can refer pain to the head and reproduce the pain patterns of tension-type HA (TTH). The present study applied massage focused on MTrPs of patients with TTH in a placebo-controlled, clinical trial to assess efficacy on reducing headache (HA) pain.
T ension-type HA (TTH) is a widespread and major health concern. The 1-year prevalence of episodic tension-type HA (ETTH) and chronic tension-type HA (CTTH) is 38% and 2% to 3%, respectively. 1,2 TTH affects daily functioning, resulting in limitations in performance and participation. 1 Although TTH is the most prevalent headache (HA) disorder, resulting in greater societal burden than migraine, investigation into interventional avenues lags other HA categories such as migraine. [3] [4] [5] Others have stressed the need for development of treatment interventions for TTH with fewer side effects than the currently recommended medications. 6 In recent years the myofascial trigger point (MTrP) has become a site of interest in the pathology of TTH. Patients with TTH exhibit increased presence and tenderness of MTrPs in pericranial muscles. There is evidence to suggest that the presence and pain sensitivity of MTrPs are sufficient to make distinctions between HA and non-HA populations. [7] [8] [9] MTrPs within the skeletal muscle are characterized by a number of physical features including a palpable tender nodule within a taut muscular band, point tenderness at the nodule, characteristic patterns of referred pain, and the presence of a local twitch response when stimulated. 10 To underscore the importance of the MTrP and its relationship to HA, a prominent and recurring theory is that the progression from episodic to chronic forms of TTH is related to prolonged nociceptive input from peripheral myofascial tissues, which sensitize the central nervous system, thereby increasing its excitability. 11, 12 Although pathogenesis of TTH remains unclear and is likely multifactorial, MTrPs have an intriguing connection to TTH in that active MTrPs can elicit referred pain phenomenon that reproduce patient reports, thus providing a direct connection between peripheral tissue and the central pain of HA. 7, [12] [13] [14] [15] [16] [17] [18] Recently, interventions directed at an MTrP have led to the reduction in local pain, referred pain intensity, and the extent of referred pain fields originating from the MTrP in both HA and non-HA populations. 19, 20 Treatment that addresses MTrPs has been emphasized as an interventional strategy for management of TTH. 21 To that end, several pilot studies with a focus on the MTrP have found positive effects in the primary clinical measures of TTH. 22, 23 Preliminary research also indicates that interventions that address the MTrP as part of a more comprehensive treatment plan may be beneficial in the management of TTH. [24] [25] [26] Two recent noncontrolled studies were designed to identify the clinical characteristics of TTH patients likely to achieve short-term success with MTrP therapy. 27, 28 In the earlier study, 4 variables were identified for predicting immediate short-term benefit (HA duration <8.5 h/d, HA frequency <5.5 d/wk, bodily pain <47, vitality <47.5) and 2 variables stood out at the 1-month follow-up (HA frequency <5.5 d/wk and bodily pain <47). The second study identified 8 prognostic factors from the history and the physical examination of TTH patients that link to treatment success of MTrP therapy for TTH. The 8 variables included 6 that are associated with MTrPs or cervical musculature: the presence of MTrPs in the suboccipitals, left sternocleidomastoid, left superior oblique; referred pain area of the right upper trapezius MTrP, the total muscle tenderness score, and the reduced cervical rotation to the left. Age below 44.5 years and a score of 18.5 or less on the Neck Disability Index questionnaire constitute the remaining 2 prognostic factors. The authors report that patients expressing 5 or more variables exhibit an increased likelihood of treatment success with MTrP therapy. Although techniques that reduce MTrP pain are a logical interventional target for TTH, no randomized, placebo-controlled trial has been conducted to determine the efficacy of an intervention focused solely on the MTrP for reducing HA pain. 29 Although many techniques exist that can have an impact on the MTrPs, massage therapy is particularly interesting due to its availability, 30 relatively low cost, 31 patient interest, 32 informality, and treatment effectiveness. 19, 33 The aim of the present study was to determine the efficacy of trigger point release (TPR) massage for reducing TTH pain in a randomized, placebo-controlled trial. Secondary aims were to determine the effects of multiple TPR massage sessions on MTrP tenderness and assess the quality-of-life variables in those with TTH.
METHODS
The present study conformed to the International Headache Society guidelines for the design of randomized clinical trials for HA. 34 Study procedures were approved by the Colorado Multiple Institutional Review Board (COM-IRB) at the University of Colorado Denver. Informed consent was obtained from all participants before study enrollment. The trial is registered at ClinicalTrials.gov, number NCT01244555.
Study Population
Participants were recruited from a large metropolitan setting near a University hospital. All participants were screened for TTH by an anesthesiologist (J.P.K.) with specialty experience in HA. Participants were recruited and enrolled between September 2010 and May 2012.
For inclusion in the study, participants had to have 2 or more HAs per week meeting the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria for TTH defined as head pain of bilateral location, pressing or tightening quality, mild to moderate intensity, and not aggravated by routine physical activity (eg, walking or stair climbing). 35 Both of the following criteria also had to be met: no nausea or vomiting in association with the HA; and no more than one of the following 2 symptoms, photophobia or phonophobia. Participants between 18 and 59 years of age were recruited. Exclusion criteria included migraine (> 1/mo), HA originating from a secondary cause (eg, cancer or injury), fibromyalgia, diabetes, major depression, neurological or cardiovascular disease, pregnancy, use of professional massage, or ultrasound (US) specifically for HA in the prior 6 months. Participants taking prophylactic medication for HA were also excluded; abortive medication was permitted provided a self-reported use for no >75% of HA episodes. All participants were screened by a massage therapist for the presence of at least 1 active MTrP in the primary (bilateral) muscles addressed (upper trapezius, suboccipital muscles, sternocleidomastoid).
Design
The study was a randomized, placebo-controlled clinical trial conducted in 3 consecutive phases: baseline (4 wk), treatment (6 wk), and run-out (4 wk). The treatment phase was divided into two 3-week phases to detect any treatment plateau ( Fig. 1 ). HA was recorded in a daily HA diary for the duration (14 wk) of the study. Immediately before the first treatment session, participants were block randomized (blocks of 6) to receive massage, placebo, or wait-listed. Individuals randomized to massage or placebo were then scheduled for twice weekly sessions over 6 weeks for a maximum of 12 treatment sessions. Participants randomized to the wait-list group did not attend intervening sessions.
All participants were informed, before consenting, that they could receive the alternate treatment (massage or US) program upon completion of the study free of charge. During the run-out phase, participants received no intervention. No patient reported initiating a new treatment intervention during the 14-week study. All interventions and assessments were conducted at the Clinical and Translational Research Center at the University of Colorado Hospital.
Interventions
Each massage or placebo session was 45 minutes in duration, administered twice per week, and separated by at least 48 hours.
Massage
All of the massage therapists who delivered that intervention had state licensure in Colorado to practice massage, prior training and work experience in the identification of MTrPs, at least 3 years of professional practice experience, and regular use of the general massage techniques used in the protocol. Massage therapists underwent two 3-hour study protocol training sessions to ensure consistent application of the massage procedure. Each massage therapist was observed by the lead massage therapist (N.B.) on 3 unannounced occasions to confirm adherence to massage protocol administration. Only minimal deviations from the protocol were observed and none detected after the first observation session. Six massage therapists participated in the study. Patients were assigned a primary therapist for the study duration based on the therapist and the patient schedules. No therapist was assigned to more than 5 patients.
Each massage session followed a standardized protocol lasting 45 minutes, consisting of 15 minutes of myofascial release to warm soft tissues of the back, shoulders, chest, and neck 36 ; 20 minutes of TPR applied bilaterally to address MTrPs in the upper trapezius, the suboccipital muscle groups, and the sternocleidomastoids 22, 37 ; the final 10 minutes consisted of postisometric relaxation directed at the right and left lateral cervical flexion, circular, or cross-fiber friction on the masseter, temporalis, and occipital-frontalis muscles, as well as gentle effleurage and petrissage to the neck and shoulders. 38, 39 The upper trapezius, suboccipital muscles, and the sternocleidomastoids were selected for TPR treatment due to the high frequency of MTrPs in these muscles that refer pain to the head and reproduce the patient's HA pain report. 16, 21, 40 MTrPs were identified using published criteria. 10 Briefly, muscles were palpated for a tender nodule along taut bands within the respective muscle groups. Force was progressively applied to the nodule with the patient instructed to verbally indicate whether they felt pain locally or in other areas (referred pain). For sites where the patient indicated referred pain, patients were asked whether the pain was familiar (eg, reproduced their typical HA). If multiple MTrPs were identified within a muscle, the MTrP that reproduced the patients' typical HA (active MTrP) was addressed. If no active MTrP was identified the most tender site was treated. TPR was applied as follows: pincer grip of sufficient force to just elicit referred pain (or 6 on a 10-point scale) was applied to the identified site. The duration was until patient verbally reported dissipation of referred pain, the therapist detected a physical softening in the MTrP, or a maximum of 60 seconds had elapsed. Up to 5 compressions were performed at each site with a 10-second rest between compressions to allow blood reperfusion. TPR has been extensively used by our research team 22, 41 and others. [42] [43] [44] Placebo Proper placebo control for massage-based studies is inherently difficult as many sham treatments lack plausibility for the health issue or could inadvertently contribute a therapeutic benefit. A proper control intervention for massage must seem plausible for the ailment, account for contextual aspects of the intervention such as patienttherapist individual time, and incorporate a tactile interaction with the patient. Detuned US meets all of these parameters as it: (1) is believable as an intervention for MTrPs 33,45-48 ; (2) controls for therapist-patient interaction;
(3) involves tactile contact with the patient; and (4) provides no potentially effective treatment. Furthermore, patients are unable to distinguish an active from an inactive US treatment, thus ensuring that blinding was maintained. 49, 50 Detuned US was administered by a nurse or nurse's aide who had received a 1-hour training on US application from a certified US technician. Nurses were used because of the high plausibility for a nurse to administer this type of intervention in a medical setting, thus enhancing the believability of the placebo intervention. Detuned-US was administered using a Dynatron 150plus (Dynatronics Corporation, Salt Lack City, UT) with display settings at 1 W/cm 2 intensity, 1.0 Mhz frequency, and 20% duty cycle. A nonfunctional soundhead (5 cm 2 ) provided by the manufacturer was used. A standardized protocol was followed to ensure consistency in its application. Patients were seated in a massage chair with detuned US administered sequentially to the 4 regions of the upper back and neck to approximate location of the left and right upper trapezius and suboccipital muscle groups. Water-soluble coupling agent (ScripHessco Ultrasound Gel; Script ScripHessco, Bolingbrook, IL) was applied to the skin surface and the soundhead moved in small overlapping circles at a rate of 2 to 3 cm/s. Each region was treated for 10 minutes with the area cleaned of coupling agent before proceeding to the next region. Each US session lasted 45 minutes.
Eight nurses or nurse's aides participated in the study; each was observed by the certified US technician on 1 unannounced visit to assess US application and confirm treatment protocol compliance. No technical deviations were observed. Both nurses and patients were blind to the nonfunctional nature of the US equipment.
Wait-list Group
A wait-list comparator group was included to assess the natural course of TTH over time. Patients randomized to this group did not receive any intervention, but completed all assessments in a time-matched manner. They maintained and returned their HA diaries similar to the massage and placebo groups.
All patients and study personnel were blind to patient group assignment until immediately before the first treatment intervention ( Fig. 1 ) when a sealed envelope was opened that designated group assignment. Envelopes containing group allocation were prepared by departmental staff not affiliated with the study, but with guidance from the study statistician.
Outcome Measures

Daily Headache Diary
Patients maintained a daily HA diary for the duration of the study (14 wk) with each phase representing 3-week (treatment phase A and B) or 4-week (baseline and run-out) intervals. Diary recordings of 3 to 4 weeks have been shown to be reliable for HA measures in research investigations. 34, 51 Patients recorded HA frequency, duration (hours and minutes), use of pain medication for HA, and HA pain intensity (100 mm visual analog scale with anchors of "no headache pain" and "maximum headache pain"). Diaries were returned by mail or directly to study personnel at 2-week intervals. HA frequency was calculated as a weekly average for each patient during the time frame measured; HA duration and intensity are presented as the average value recorded per HA during the time frame measured; nonprescription medication use for HA was calculated as a weekly sum of the number of doses taken.
Perceived Clinical Change
Participant-perceived change in HA pain was recorded on a 15-point scale ranging from À 7 to + 7. 52 Descriptors were provided with the numerical range where 0 was associated with "about the same"; ± 1, "a tiny bit better/ worse"; ± 2, "a little bit worse/better"; ± 3, "somewhat worse/better"; ± 4, "moderately worse/better"; ± 5, FIGURE 1 . Study timeline for the 14- week clinical trial depicting the 4-week baseline, two 3-week treatment phases, the 4-week runout, and timepoints for outcome measure assessments. HA, headache; PCC, perceived clinical change; PPT, pressure-pain threshold; QoL, quality of life.
"quite a bit worse/better"; ± 6, "a great deal worse/ better"; ± 7, "a very great deal worse/better." Patients recorded perceived change in HA pain just before the final treatment (end of the treatment phase) and at the end of the 4-week run-out relative to how they felt at the start of treatment.
Pressure-pain Threshold (PPT)
PPT was assessed bilaterally in the upper trapezius and subobccipital muscles using pressure algometry (Wagner FPN 50 algometer, Wagner Instruments Inc., Greenwich, CT). Briefly, muscles were palpated for MTrPs as described above. 10 When multiple MTrPs were identified, measurement was conducted at the site that generated referral pain reproducing the patients' typical HA (eg, active MTrP). If no active MTrP was identified, assessment was made at the most tender site identified. The algometer tip was placed over the site and force slowly applied until the patient verbally indicated that sensation changed from pressure to pain. The average of 3 assessments at the same site is reported; no change in PPT was detected across replicate measures (all P's > 0.23 for each muscle group). A 20-second recovery was given between measurements. PPT was conducted immediately before randomization into treatment group and the final (12th) treatment visit, or, in the case of the wait-list group at a time-matched period 6 weeks after the first assessment. In all cases, the final PPT assessment was conducted at least 48 hours after any previous intervention session. Measurement of PPT in the SCM was not conducted due to the sensitive location and the lack of a smooth, hard surface (eg, bone) from which to apply constant pressure. Data are presented as kilogramforce (kgf). Owing to technical reasons it was not possible to blind the assessor to patient treatment group assignment.
Quality of Life
The impact of HA on daily life was assessed by 2 validated questionnaires that capture different aspects of HA-associated disability. Questionnaires were administered at 3 timepoints: (1) the end of the baseline phase (immediately before randomization); (2) the end of the treatment phase (6 weeks later); (3) and at the end of the run-out. Assessment at the end of treatment occurred just before the final treatment and at least 48 hours after any previous intervention.
(1) The Headache Disability Inventory (HDI) is a principal measure of disability focusing on the emotional and functional components of HA. 53 The HDI consists of 25 questions based on items derived empirically from case history responses of participants with HA. Responses are scored requiring a "yes," 2 points; "sometimes," 1 point; or "no," 0 points. A total score is computed by summing all scores resulting in an individual HDI score ranging from 0 (no disability) to 100 (severe disability). A decrease in the total HDI score of Z16 points is considered to be a clinically significant improvement. 54 The HDI has good internal consistency (0.89), robust short-term and long-term retest reliability (0.83), and good construct validity. 53, 54 (2) The Headache Impact Test (HIT-6) is a validated measure for assessing the quality of life in patients with HA as a function of HA frequency. 34, 55 The HIT-6 consists of 6 items (pain, social functioning, role functioning, vitality, cognitive functioning, psychological distress) where respondents select 1 of 5 options:
"never," 6 points; "rarely," 8 points; "sometimes," 10 points; "very often," 11 points; "always," 13 points. Total score ranges from 36 to 78 points. A decrease of 2.3 to 8 points among patients with chronic daily HA reflects improvement in HA that is considered clinically significant. 52, 56 The HIT-6 has good internal consistency (Cronbach a 0.89), and sound test-retest reliability (0.80). 57
Sample Size Calculation
An a priori power analysis was conducted assuming b = 0.20, a = 0.05, and using effect size estimates from data obtained from the published research for the primary HA indicator (HA frequency) in a preliminary study of massage intervention for TTH. 22 On the basis of an effect size (Cohen d) of approximately 0.84 for HA frequency enrollment of 20 participants per group was anticipated to provide at least 80% power for HA frequency and allow for at least a modest amount of attrition (15%) during the study.
Statistical Analysis
All analyses were performed in SAS version 9.2. All outcomes, with the exception of perceived clinical change, were modeled in a multilevel modeling framework in SAS Proc Mixed as linear-mixed models. The models included a treatment main effect to determine an overall difference between groups and a time main effect to determine whether scores changed over time. The primary interest was in the treatment by time interaction to address the primary hypothesis that changes over time differed by group. If a significant treatment by time interaction was observed (eg, P < 0.05), simple effects tests were conducted to examine how scores changed over time within each of the 3 groups. The same modeling framework was followed for all outcomes, although there were 4 timepoints for HA diary outcomes (baseline, first half of treatment [phase A], second half of treatment [phase B], and end of run-out), 2 timepoints for PPT outcomes (baseline and end of treatment), and 3 timepoints for the HDI and HIT-6 (baseline, end of treatment, end of run-out). Several potential confounding variables were identified: age, sex, race/ethnicity, HA diagnosis (chronic or episodic), years with TTH, recent history of professional massage, activity level, depression, and anxiety. Each potential covariate was tested to determine whether it differed by condition or was related to the primary HA outcomes. None of these tests were statistically significant. Consistent with prior literature, the perceived clinical change score was broken down into 4 categories: 0 = no change; ± 1 to ± 3 = small change; ± 4 to ± 5 = moderate change; and ± 6 to ± 7 = large change. 58 The Fisher exact test was used to test for differences in the proportion of those reporting no, small, moderate, or large change across the 3 conditions. ANOVA models were used to assess mean change in HA frequency from baseline to the end of treatment and run-out across the 4 change categories (collapsed across condition).
RESULTS
A total of 184 individuals were assessed for study eligibility; 69 met the eligibility criteria and were enrolled (Fig. 2) . Five participants were removed from the study before randomization due to incorrect HA diagnosis based on the HA diary recordings; 2 participants withdrew, before randomization, due to conflict with scheduling. Sixty-two participants were randomized to massage (20) , placebo (21) , or wait-list (21) groups. Six participants (3 in massage, 2 in placebo, 1 in wait-list) subsequently withdrew or were lost to follow-up. To examine whether the data from those who completed the study could generalize to those who dropped, the completer group was compared with the dropped group on baseline demographic and HA variables. Of 25 tests conducted, the only significant difference between groups was on HA duration, where duration was significantly higher in the group who dropped due to a single outlier. Overall, this provides evidence that those who dropped were, on an average, similar to those retained. Table 1 depicts demographic information for the 56 participants analyzed in the study, by treatment group. The 3 groups did not differ statistically in terms of any of the demographic variables examined. On an average, participants were 33.5 years old and the majority were female, white, employed full time, and had experienced TTH for an average of 8.9 years (SD = 6.9). Participants attended a mean of 11.6 (SD = 1.0) massage and 11.5 (SD = 0.84) placebo sessions of the planned 12 sessions (P = 0.96). Table 2 depicts the results of the analyses examining treatment effects on changes in HA outcomes over time. Means ± SE are presented for each timepoint, by the treatment group. Treatment group differences were detected in changes in HA frequency over time (F 6,52 = 2.65, P = 0.026). Post hoc analysis identified that HA frequency decreased for both massage (P = 0.0003) and placebo (P = 0.013) groups relative to their baseline but not for the wait-list group (P = 0.098). No statistical difference was detected between the massage and placebo treatment groups (P = 0.26). The pattern of means for HA frequency are also illustrated in Figure 3 , and, as shown, the largest difference between conditions was during the second phase (phase B) of the treatment (P = 0.033). No significant treatment group differences were detected for HA duration, HA intensity, or medication use.
Assessed for eligibility (n=184)
Consented (n=69)
Excluded ( Table 3 shows group effects on quality-of-life measures across time. Significant condition effects were observed on changes in HDI (F 4,52 = 3.26, P = 0.019) and HIT-6 (F 4,52 = 3.27, P = 0.018). Post hoc tests showed a significant decrease in HDI scores in the intervention group (P = 0.0003) but not in the placebo (P = 0.06) or wait-list (P = 0.39) groups; a significant change in HIT-6 scores was detected over time in both the intervention (P = 0.0002) and placebo (P = 0.011) groups but not in the wait-list group (P = 0.52).
The perceived clinical change in HA pain is presented in Table 4 . In the first set of analyses, the percentage of patients reporting changes in HA pain across the 3 conditions was assessed. The results of the Fisher exact test comparing reported change across the 3 conditions was significant both at the end of treatment and at the end of run-out. At posttreatment, the vast majority of those in the massage condition reported moderate or large improvement (84.7%), compared with 50% in the placebo group and 0% in the wait-list group (P < 0.001). In contrast, 82.4% of those in the wait-list condition reported no change. These patterns were maintained at the end of runout where 64.3% of those in the massage group reported moderate or large improvement compared with 36.8% in the placebo condition and 6.25% in the wait-list control condition (P = 0.002). Table 4 also shows the mean change in HA frequency that corresponds to change category membership. There were significant differences in the change in HA pain across the 4 categories at both assessment timepoints. For example, a reduction of approximately 2 HAs (1.88 to 2.11) per week corresponded to a patient reported "large" perceived change.
Changes in the MTrP PPT from the start to the end of the 6-week treatment phase are shown in Table 5 . There was a significant time by treatment interaction for all the 4 sites tested (F values ranged from 4.49 to 7.91, P values ranged from <0.001 to 0.015). Post hoc analyses showed that scores significantly improved in the massage group (P values ranged from <0.001 to 0.002 across outcomes), but did not change in the placebo and wait-list groups (all Ps > 0.17).
DISCUSSION
The present clinical trial found that the 6-week programs of massage therapy, with an emphasis on MTrPs in key cervical musculature, or placebo (detuned US) were both efficacious for reducing HA frequency in a mixed population of ETTH or CTTH. No statistical difference between massage and placebo treatments was found for HA frequency as recorded on the HA diary, although selfreport of the perceived clinical change detected greater improvement for those who received massage at both immediately postintervention and end of the run-out timepoints. Group or time changes to secondary HA measures (intensity and duration) were not impacted by massage or placebo, nor was medication use changed as measured by the number of weekly doses consumed for HA pain.
Statistical change for secondary non-HA, quality-oflife measures was noted in both the HDI and HIT-6 questionnaires, with post hoc statistical separation between massage and placebo groups detected for the HDI, but not the HIT-6. Only the change in the HIT-6 achieved the threshold to be considered clinically significant. 56 Finally, assessment of PPT at MTrPs of the upper trapezius and suboccipital muscles increased for patients who received massage, but did not change for placebo or wait-list groups. This measure was conducted at least 48 hours after any treatment indicating a sustained effect in PPT for those who received massage.
The treatment phase of the present study was divided into 2 halves (phases A and B) to help identify a possible treatment plateau. For the massage intervention, a small reduction in HA frequency was detected from the baseline to the first half (0.34 HA/wk) of intervention; greater reduction in HA frequency (1.01 HA/wk) was noted during the second half of the treatment phase. Aggravation of MTrPs can lead to increased local pain. 59 With direct pressure from TPR massage at MTrPs coupled with uncertainty of optimal treatment pressure, it is possible that multiple sessions are needed to effect meaningful change or that gains from early sessions are counter-balanced by losses from aggravation of MTrPs. The effect of placebo intervention on HA frequency was the reverse, that is, greater reduction in HA frequency occurred during the first 3 weeks (0.6 HA/wk) with an additional gain of about half that during the second half of the treatment phase (0.29 HA/wk). It is not clear if additional massage or placebo sessions beyond the 12 would provide additional benefit although 75% of those receiving massage and 53% in the placebo group reported a belief that additional sessions would be beneficial.
The origin of pain in TTH remains unknown, although both peripheral and central factors likely play a role in its pathophysiology. ETTH and CTTH populations report increased presence of MTrPs in pericranial musculature 7, 13, 15, 40 that, when stimulated, precisely reproduce the typical HA report. It was hypothesized that massage of MTrPs in the cervical musculature would result in a reduction in HA pain. Our study provides some evidence that increase in MTrP PPT is a mechanism underlying the positive effect of intervention on HA frequency. Supplementary mediational analysis showed that massage intervention predicted change in MTrP PPT from the beginning to end of the treatment phase (P < 0.001) and that the change in PPT predicted a decrease in the average number of HAs from the baseline to the follow-up period (P < 0.001). These analyses show that MTrP PPT change may be one mechanism by which reduction in HA occurs. However, as HA frequency also decreased in the placebo condition, even though the placebo treatment did not impact trigger point tenderness, a separate mechanism for HA reduction is likely. As the placebo treatment contained all aspects of the massage treatment except an active intervention, it is probable that some of the observed gains in the massage group are related to contextual factors of the intervention.
A qualitatively altered pain perception and generalized hyperalgesia lead to the current thought that HA pain in CTTH is the result of chronic central sensitization, suggesting differing pain generation mechanisms between ETTH and CTTH while questioning the role of MTrPs once CTTH has been established. 11, 60 Active MTrPs in TTH patients could be a source of frequent noxious stimuli to the CNS that assists in transforming ETTH to CTTH. Our study, suggests that a reduction in pericranial myofascial nociception (eg, increased PPT) remains an important component for reducing HA frequency in both frequent ETTH or CTTH.
Identification of individuals with TTH likely to respond to MTrP-based therapies is important for The massage protocol used in the study was highly structured, with muscles most commonly associated with pain referral to the head (upper trapezius, suboccipitals, and sternocleidomastoid) addressed for MTrPs during each visit. Although this consistency enhanced the reproducibility of the procedure, it may have limited treatment efficacy as pericranial muscles (eg, temporalis, superior oblique, masseter, levator scapula) also generate referred pain from MTrPs and may contribute to TTH. 40, 61 In the present study, some patients had few active MTrPs in the muscles addressed, which could have resulted in limited improvement if MTrPs in other muscles were active in contributing to HA. Freedom for the therapist to palpate for, and address, MTrPs in a patient's most problematic muscles, in a pragmatic study design, would be helpful in identifying the treatment potential of TPR massage for TTH.
Several limitations in our study should be noted. The study was powered to identify whether a TPR-focused massage could reduce HA pain relative to a wait-list population rather than compared with placebo intervention. Although no statistical difference was observed from diary recordings between TPR massage and placebo for HA frequency, self-report did indicate a difference in overall HA pain. Further research is needed to establish if a difference between placebo and TPR massage exists. We screened for patients presenting with TTH and excluded those with >1 migraine per month. The selection criteria resulted in a population largely free of non-TTH HA, which suggests that the results are not generalizable to individuals with other HA types. Furthermore, while individuals with either frequent ETTH and CTTH were recruited, the individuals who responded and met the enrollment criteria were predominantly CTTH or experienced ETTH with 8 or more HAs per month; suggesting that the study findings are most relevant to those with greater HA frequency.
To our knowledge, this study marks for the first time, a placebo effect for a TTH interventional study. Inclusion of a placebo intervention for HA studies has been limited, especially for studies of TTH. 62 It is an important consideration because investigations involving placebo interventions can have profound implications. 63 Blinding of both patients and those who administer a physical intervention is extremely difficult, but of critical importance. Interventional studies for TTH involving medications have found that placebo medications may be as effective as an active medication, highlighting the need for placebo-controlled trials in body-oriented therapies, as well. 64 For studies involving physical therapies, placebo in the form of medication fails to address potentially important contextual aspects of an intervention such as patient-therapist individual time as well as physical interactions. Furthermore, a placebo treatment that focuses on a nonaffected area (eg, foot massage) would likely raise doubts among participants regarding its potential value and possibly leading to participant drop-out. Blinding of the technician who administers treatment is also important to study integrity as patients may be influenced by practitioner behavior. 65 We addressed this last concern by keeping social interaction between patient and practitioner to a minimum and keeping the US technicians blind to the nonfunctional nature of the device.
Recently, MTrPs have received increased attention for their role in TTH. Although massage that focused on MTrPs and placebo both reduce TTH frequency, their respective mechanisms of action for HA reduction may be different. Our findings suggest that reduction in MTrP PPT may be an important treatment avenue for addressing TTH pain although the contextual factors associated with intervention also contribute to improvement in HA frequency. 
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